NYLT
GILD icon

New York Life Trust’s Gilead Sciences GILD Stock Holding History

New York Life Trust’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$15K Sell
214
-2,441
-92% -$172K 0.73% 25
2016
Q4 		$190K Buy
2,655
+110
+4% +$8.18K 0.9% 27
2016
Q3 		$201K Buy
2,545
+181
+8% +$14.7K 0.99% 25
2016
Q2 		$197K Sell
2,364
-428
-15% -$38K 0.96% 27
2016
Q1 		$256K Sell
2,792
-101
-3% -$9.11K 1.11% 23
2015
Q4 		$293K Buy
2,893
+21
+0.7% +$2.19K 1.26% 19
2015
Q3 		$282K Sell
2,872
-35
-1% -$3.89K 1.25% 15
2015
Q2 		$340K Sell
2,907
-236
-8% -$25.8K 1.41% 10
2015
Q1 		$308K Sell
3,143
-4
-0.1% -$406 1.23% 12
2014
Q4 		$297K Buy
3,147
+1,074
+52% +$111K 1.17% 20
2014
Q3 		$221K Buy
2,073
+1,284
+163% +$126K 0.91% 25
2014
Q2 		$65K Buy
789
+29
+4% +$2.26K 0.27% 134
2014
Q1 		$54K Buy
760
+39
+5% +$3.06K 0.24% 135
2013
Q4 		$54K Sell
721
-2,251
-76% -$157K 0.25% 137
2013
Q3 		$187K Sell
2,972
-665
-18% -$39.7K 0.94% 26
2013
Q2 		$186K Buy
+3,637
New +$190K 0.86% 29

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

New York Life Trust's GILD Position: Q1 2017 in Review

New York Life Trust reduced its Gilead Sciences (GILD) stake by 92% in Q1 2017, selling an estimated $172K and leaving 214 shares worth $15K. The position accounts for 0.73% of the portfolio, ranked #25.

New York Life Trust first reported a position in GILD in Q2 2013 and has held it in 16 quarters since. The position peaked at $340K in Q2 2015. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • New York Life Trust held 214 shares of Gilead Sciences worth $15K as of Q1 2017.
  • New York Life Trust sold 2,441 Gilead Sciences shares in Q1 2017, an estimated $172K.
  • Gilead Sciences made up 0.73% of New York Life Trust's portfolio in Q1 2017, its #25 holding.
  • New York Life Trust first reported a position in Gilead Sciences in Q2 2013 and has held it in 16 quarters since.
  • New York Life Trust's Gilead Sciences position peaked at $340K in Q2 2015.
  • 1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on New York Life Trust's 13F filing for Q1 2017, filed 12 May 2017.